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A B S T R A C T
Light triggered drug delivery systems offer attractive possibilities for sophisticated therapy, providing both
temporal and spatial control of drug release. We have developed light triggered liposomes with clinically ap-
proved indocyanine green (ICG) as the light sensitizing compound. Amphiphilic ICG can be localized in different
compartments of the liposomes, but the effect of its presence, on both triggered release and long term stability,
has not been studied. In this work, we report that ICG localization has a significant effect on the properties of the
liposomes. Polyethylene glycol (PEG) coating of the liposomes leads to binding and stabilization of the ICG
molecules on the surface of the lipid bilayer. This formulation showed both good storage stability in buffer
solution (at +4–37 °C) and adequate stability in serum and vitreous (at +37 °C). The combination of ICG within
the lipid bilayer and PEG coating lead to poor stability at elevated temperatures of +22 °C and+37 °C. The
mechanisms of the increased instability due to ICG insertion in the lipid bilayer was elucidated with molecular
dynamics simulations. Significant PEG insertion into the bilayer was induced in the presence of ICG in the lipid
bilayer. Finally, feasibility of freeze-drying as a long term storage method for the ICG liposomes was demon-
strated. Overall, this is the first detailed study on the interactions of lipid bilayer, light sensitizer (ICG) and PEG
coating on the liposome stability. The localization of the light triggering agent significantly alters the structure of
the liposomes and it is important to consider these aspects in triggered drug delivery system design.
1. Introduction
Targeted delivery of drugs using external light trigger is feasible in
light-accessible organs, e.g. eye and skin, and it may offer several
benefits compared to passive drug leakage from the drug carrier. In
principle, laser triggered drug release might enable therapy adjust-
ments according to the progression of the disease and cyclic changes in
the body [1]. The parameters of the laser based remote triggering (i.e.
beam diameter, exposure duration, wavelength and light intensity) can
be adjusted in a versatile manner for the specific drug delivery system
and target tissue [2–4].
Liposomes are a robust and well-studied class of drug delivery sys-
tems (DDS) [5–7]. They are used in many drug therapies, including the
treatment of cancer, infections and other diseases [8–10]. Liposomes
can be prepared using a variety of methods and the resulting for-
mulation properties can be adjusted with processing parameters [11].
Passive drug release from liposomes is often erratic and inadequate [6,
12], but the release can be enhanced by using external triggering me-
chanisms [13]. Various light triggering mechanisms for liposomes have
been developed, i.e. photo-cleavage, polymerization and energy con-
version to heat [5, 14–19]. In particular, infrared (IR) light has been
found to be a very attractive triggering method, due to superior tissue
penetration and safety [5, 20].
We have previously developed light triggered liposomes using in-
docyanine green (ICG) as the light sensitizing agent for delivery and fast
release of small compounds and macromolecules [21, 22]. The for-
mulation released small and macromolecular contents after five seconds
of near infra-red light exposure [22]. ICG is a fluorescent dye that has
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been approved by European Medicines Agency (EMA) and the U.S.
Food and Drug Administration (FDA) for clinical imaging [23, 24] re-
lated to angiography and lymphatic function [25–28]. This indicates
that ICG is safe to use in humans. The use of ICG in light activated
liposomes is based on the ability of ICG to convert absorbed light en-
ergy (at about 800 nm) to heat [27–32]. Due to its amphiphilic struc-
ture, ICG can be integrated into the liposomal lipid bilayer or be
wrapped into the polymeric coating of the liposomes, for example
polyethylene glycol [22] that is used to increase the circulation time of
intravenously administrated liposomes in the blood stream [33, 34].
Obviously, the light triggered liposomes should release their contents
based on light triggering, but otherwise they should show adequate
chemical, physical and physiological stability [35]. ICG degrades upon
light activation [21], but the effect of ICG on the liposome stability has
not been elucidated previously.
We investigated the impact of ICG on the stability of the liposomes
in the presence of buffers, serum and vitreous humor of the eye.
Different sites of ICG localization in the liposomes (lipid bilayer or
polymeric sheath) were investigated experimentally and in silico using
molecular dynamics simulations. Furthermore, freeze drying of the li-
posomes was explored as potential stabilization procedure.





phoethanolamine (DSPE) and 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG)
were bought from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). All
other compounds were bought from Sigma-Aldrich (St. Louis, MO,
USA).
2.2. Preparation of ICG liposomes
The lipids were dissolved in chloroform in molar ratios of
75:15:10:4 (DPPC / DSPC / Lyso PC / DSPE-PEG or DSPE) prior to the
liposome preparation. The liposomes were formed by the thin film
hydration method followed by extrusion through a polycarbonate
membrane as described earlier [22]. ICG was integrated into the lipid
bilayers using the following procedure. ICG (0.2 μmol) was dissolved in
methanol and mixed with the lipids in chloroform prior to evaporation
of the organic solvent. For ICG entrapment to the PEG layer, the same
amount of ICG was added to the aqueous hydration solution. The thin
lipid layer was hydrated with 500 μL of HEPES buffer solution (20mM
HEPES, 140mM NaCl, pH 7.4) or calcein solution (60mM, 280mOsm/
kg, pH 7.4). The lipids and hydration solution were incubated in
a+60 °C water bath forming polydisperse liposomes. The liposomes
were extruded 11 times at +60 °C through a polycarbonate membrane
with pores of 100 nm (diameter) with a syringe-type extrusion device
(Avanti Polar Lipids). Thereafter, the liposomes were quickly cooled
and stored in a refrigerator. The free calcein and ICG in the liposome
suspension were removed by gel filtration through a Sephadex G-50
(Sigma-Aldrich) column, where HEPES buffer solution was used for
elution. The lipid concentration of the purified samples was 1.5 mM,
and the ICG concentration was 30 μM.
2.3. Analysis methods
2.3.1. Temperature-induced content release
Contents release from the liposomes was studied at temperatures
ranging from +35 to +50 °C on a thermomixer with an Eppendorf
heating block (Eppendorf AG, Hamburg, Germany) as described earlier
[22]. Briefly, the calcein encapsulating liposomes were heated for
10min while shaking at 300 rpm. Following this their fluorescence was
measured with a Varioskan Flash plate reader (Thermo Fisher Scientific









where Ft is the fluorescence of the sample at a specific measurement
time point, F0 is the background fluorescence of the sample, and F100 is
the fluorescence of complete release of the model drug compound by
disruption of the lipid bilayer with 10 μL of 10% Triton-X.
2.3.2. Light-induced content release
The light-induced contents release was determined as described
earlier [5]. Briefly, the purified liposome sample (500 μL) was placed in
the thermomixer (Eppendorf AG) and heated to +37 °C. The light-
triggering was done with 808 nm light for 5 s using a laser power of
9.7W/cm2 (Modulight, Tampere, Finland). The fluorescence of released
calcein was analyzed with a Varioskan Flash plate reader and release
patterns were calculated with Eq. 1.
2.3.3. Differential scanning calorimetry
Differential scanning calorimetry (Mettler Toledo DSC823e, Mettler-
Toledo GmbH, Greifensee, Switzerland) was used to determine the
phase transition temperatures (Tm) of the liposomes. Briefly, 20 μL of
the liposome sample was pipetted to aluminum pan and sealed by an
aluminum lid with two small holes to prevent pressure buildup. The
sample and reference pans were heated using a linear temperature
gradient alongside a reference pan in a nitrogen environment. The
phase transitions were seen as endothermic peaks in the thermographs
(analyzed with STARe software, Mettler Toledo). The phase transitions
of the freeze-dried samples were analyzed from powder samples after
reconstitution with purified water.
2.3.4. Size analysis and zeta potential of liposomes
The size of the liposomes for the stability studies was analyzed with
a Zetasizer APS dynamic light scattering automated plate sampler
(Malvern Instruments, Malvern, United Kingdom) and reported as size
distributions by particle number and polydispersity index (PdI). The
zeta potential was measured with Zetasizer ZS (Malvern Instruments).
The size and the zeta potential of the liposomes before and after freeze-
drying process were measured with a Zetasizer Nano ZS (Malvern
Instruments), because these experiments were carried out at a different
location.
2.3.5. Stability of ICG
The ICG degrades quickly in aqueous solutions and loses its absor-
bance peak at 800 nm [36]. Absorbance is used to measure the leakage
from the liposomes and degradation of the ICG molecules. The ICG
amount was analyzed using a Varioskan Flash plate reader in black
clear bottom well plates (Corning Inc., Corning, NY, USA). Absorbance
of 100 μL samples were measured at a wavelength of 800 nm. The






where ICGt is the absorbance at the specific time point and ICG0 is the
absorbance at the start of the experiment.
2.4. Stability of liposomes in buffer solution, vitreous and serum
The liposomes with ICG and encapsulated calcein (25% of the total
volume, 0.375mM) were incubated up to 15 days in HEPES buffer,
porcine vitreous or human serum at +4, +22, and+37 °C. Samples
were collected and analyzed at several time points during the storage.
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The size distribution of the liposomes, calcein release (Eq. 1), and ICG
stability (Eq. 2) were determined during the storage as described above.
2.4.1. Isolation of the porcine vitreous
The porcine vitreous was obtained using a method described earlier
with modifications [37]. Fresh porcine eyes were bought from a
slaughter house (HK Ruokatalo, Forssa, Finland) and refrigerated
during the transport. Extraocular tissue was cleaned from the eyes with
scissors, and the eyes were dipped in ethanol and then in phosphate
buffered saline (PBS) before cutting the eye ball. The eyes were cut
circumferentially behind the limbus, and then the anterior part of the
eye and the lens were removed. The vitreous was removed from the eye
cup and pooled into a plastic tube. The pooled vitreous humor was
homogenized with a glass plunger on an ice bath. The vitreous was
centrifuged at 3200 x g (+4 °C) for 60min. The resulting supernatant
was filtered through 0.45 μm and 0.22 μm syringe filters and stored at
−80 °C before use. The pH of the vitreous is known to change from
neutral pH to about 8 after removal from the eye [38]. The studied
liposomes and ICG are not pH sensitive [36], and thus this change in pH
is unlikely to significantly affect the results.
2.4.2. Human serum
Blood was drawn from seven healthy and fasted male human donors
using Vacutainer glass tubes without clot activator (BD, Franklin Lakes,
NJ, USA). Permission for research use of blood was obtained from
Helsinki University Hospital. The volunteer donors had provided their
informed consent for research use and the samples were anonymized.
The blood was left to clot for 30min at +22 °C. The blood samples were
first centrifuged at 2500×g for 5min and the supernatant was col-
lected. The supernatant was centrifuged again at 3500×g for 5min.
Collected serum fractions from all donors were pooled under aseptic
conditions and stored in aliquots at −80 °C.
2.5. Degraded ICG exposure
Intense light exposure at about 800 nm has been shown to degrade
the ICG molecules [21]. Therefore, the effect of degraded ICG molecules
on content leakage from the liposomes was determined. In order to
generate degraded ICG, the molecules in HEPES buffer without the li-
posomes were exposed to laser light (808 nm, 9.7W/cm2) for 20min.
Calcein containing ICG liposome formulations with and without PEG
were incubated for 1 h or 24 h at +37 °C with 15 μM, 30 μM, 60 μM or
300 μM of initial ICG. The calcein release was measured and calculated
as described above.
2.6. Molecular dynamics simulation of the ICG and lipid bilayer
To provide added insight into the effect of ICG localization and PEG
on the liposome bilayer we performed additional analysis of the MD
trajectories described in our previous study [22]. In brief, the simulated
system consisted of a lipid bilayer composed of 22 DSPE-PEG, 78 DSPC,
52 lyso PC, and 360 DPPC molecules, hydrated by 52,447 water mo-
lecules with a physiological salt concentration; 8 ICG molecule were
present in the system and 172 Na+ and 142 Cl− ions were added to
achieve both the desired salt concentration and charge neutrality. Two
models of a PEGylated bilayer were constructed. In the first ICG was
placed in the water phase (Formulation A), and in the second ICG was
placed inside the lipid bilayer (Formulation C). As a reference system,
we a used a bilayer with the same composition, but without PEGylation
(Formulation B): all DSPE-PEG lipids were replaced by DSPC. All mo-
lecules and ions were parameterized using the all-atom optimized po-
tentials for liquid simulations (OPLS-AA) force field [39] with addi-
tional parameters derived specifically for lipids [40, 41]. The TIP3P
model of water was used [42]. All simulations were performed using
the GROMACS 4.6.6 software package [43]. Once equilibration was
achieved, all systems were simulated for a total of 100 ns at a
temperature of +37 °C and 1 bar pressure. Further details regarding
ICG parameterization, system setup, and all other simulation protocols
not mentioned here are provided in the previous study [22].
In order to characterize the properties of the lipid bilayers, we used
several analysis tools available within the GROMACS 4.6.6 suite; these
include measuring the mass density profile and molecular order para-
meter. Additionally, we visualized the system using VMD 1.9.3. The
molecular order parameter, SCD, is defined as






where θi is the angle between a C-D bond (CeH in simulations) of the ith
carbon atom and the bilayer normal. The angular brackets denote
averaging over time and over relevant C-D bonds in the bilayer. The
mass density profile is a measure of the number of a specific atom, atom
group, or entire molecules located at specific positions normal to the
plane of the lipid membrane, i.e. where the molecule sits in the mem-
brane.
2.7. Freeze-drying of ICG liposomes
Empty liposomes, which were diluted with Milli-Q water after ex-
trusion, were freeze-dried in a Linkam thermal stage (THMS350 V,
Linkam Scientific Ltd., Tadworth, Surrey, UK), which was connected to
a liquid nitrogen pump, temperature controller and vacuum pump. The
settings were controllable through the Linksys software provided by
Linkam. A 15mm diameter object glass was used as base for the sample
and placed directly on the heating block. Two freezing ramps to −40 °C
were tested: 10 °C/min and 2 °C/min. Drying was done at −20 °C and
0 °C for the primary and secondary drying steps respectively. Duplicates
were freeze-dried for each combination of lyoprotectant concentration,
lyoprotectant type (sucrose and trehalose, Sigma-Aldrich) and freezing
rate. Trehalose and sucrose were chosen as lyoprotectans since they are
widely used in the literature [44–46]. Lyoprotectant stock solutions
(0.9M) were added to the liposome solutions at molar ratios of 1:3, 1:5,
1:7, 1:10 and 1:20, corresponding to sucrose or trehalose concentra-
tions of 4.5, 7.5, 10.5, 15 and 30mM, respectively.
2.8. 31P NMR spectroscopy
31P NMR spectroscopy was used to characterize the phospholipid
bilayer of the liposomes [47–50]. Concentrated samples of the for-
mulations without calcein were prepared in 700 μL of D2O as described
above (60 μmol of total lipids). The 31P NMR spectra were acquired on a
Bruker Ascend 400MHz – Avance III HD NMR spectrometer (Bruker
Corporation, Billerica, MA, USA) at 161.98MHz equipped with a 5mm
BBO SmartProbe™ with z-axis gradients. A zgpg30 pulse sequence in-
cluding broadband 31Pe1H decoupling was used for the acquisition.
The FID files were acquired with acquisition parameters set to 2048
scans, 5 s relaxation delay and measured at +27, +37, +39
and+ 50 °C, respectively. The recorded FID files were processed with
MestReNova 12.0.1 software (Mestrelab Research, Santiago de Com-
postela, Spain) to obtain the reported spectra.
2.9. Statistical analyses
In the freeze-drying experiments the results were analyzed using
GraphPad Prism 5. To assess the effect of sugar concentration on par-
ticle size and PdI, one-way ANOVA with Tukey post-hoc testing was
applied. To assess the difference between the two sugars or freezing
rates at different concentrations, two-way ANOVA with Bonferroni
post-hoc testing was used. The post-hoc tests were only done when the
ANOVA was significant. In the other experiments Student's t-test was
used to evaluate the statistical significance between the sample groups.
The differences between the results were considered to be significant
when the p-values were< 0.05.
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3. Results
3.1. Characterization of the ICG liposomes with variable ICG localizations
Three formulations with different ICG loading methods were pre-
pared (Table 1). Formulation A consisted of PEGylated liposomes with
ICG in the aqueous hydration solution, which means that the ICG is
bound and stabilized by the PEG chains outside the lipid bilayer [22].
Liposomes in formulation B were lacking PEG, and ICG was mixed with
the phospholipids prior to the chloroform evaporation. In formulation
C, the ICG was mixed with the phospholipids and the liposomal com-
position included also PEG. The formulations had comparable amounts
of ICG with measured absorbance (800 nm) of 0.31 ± 0.05,
0.31 ± 0.02 and 0.28 ± 0.03, for formulations A, B and C, respec-
tively. The liposomes had homogenous initial sizes of about 100 nm
with the formulation B showing the largest mean diameter (Table 1).
All formulations had a slightly negative surface charge in the range of
−3.28mV to −4.68mV (Table 1).
Calcein release from the liposomes at increasing temperatures was
measured (Fig. 1, top). Formulations A and B showed good stability up
to +37 °C, and calcein release was increased at higher temperatures.
Formulation C was the leakiest one, showing 10% release at +37 °C and
57% at the temperature of +39 °C. Formulations A and B at +39 °C
released 20% and 39% of the calcein, respectively.
The differential scanning calorimetry measurements showed only
negligible differences between the formulations (Fig. 1, bottom left).
The onset of the phase transition started at +42–43 °C for all for-
mulations. Likewise, the peaks of phase transitions were at same tem-
perature for all formulations.
After light exposure (5 s of 808 nm laser light at +37 °C) calcein
release from the liposomes was 21%, 26% and 34%, for formulations A,
B and C, respectively (Fig. 1, bottom right). Notably, formulation C
showed significant passive calcein release of about 10% during the
experiment.
3.2. Stability of liposomes in various matrices
3.2.1. Stability in aqueous buffer solution
The stability of all formulations was studied for 12 days at +4, +22
and+37 °C (Fig. 2). Each formulation retained their initial size
(Table 1) during the test. The absorbance of ICG for 800 nm light dis-
appears upon its degradation [21] allowing stability measurements.
Degradation of about 10% was seen during the first day in all for-
mulations at all temperatures (Fig. 2). At +4 °C, the ICG remained
stable from 1 day onwards, whereas after 12 days at +22 and+ 37 °C
significant ICG degradation was seen in formulation C (40% and 32% of
ICG remaining at +22 and+37 °C, respectively) and slower degrada-
tion in formulations A and B.
No significant calcein release was observed during 12 days at +4 °C
(Fig. 2). At +22 °C, formulations A and B remained stable, but for-
mulation C leaked 10% of the calcein dose during 12 days. At +37 °C,
all of the formulations showed some contents leakage. After 12 days
formulations A, B and C, had leaked 7%, 11% and 24% of the calcein,
respectively.
3.2.2. Stability in porcine vitreous and human serum
The stability of all formulations was studied in two relevant biolo-
gical environments, serum and vitreous, at +37 °C (Fig. 3). No sig-
nificant change in size was seen in 6 days, but the liposomes seem to
become more polydisperse (average PdI of 0.47). This may be due to
the interference of serum and vitreal components, and thus the actual
size of the liposomes may not be reliably assessed. After 6 days, the
samples showed increasing amount of cloudiness and sedimentation
from presumed natural aggregates of the serum and the vitreous, thus
preventing further size analyses.
The amount of intact ICG decreased by 50–60% in serum during
15 days in all formulations. The stability of the liposomal ICG was
better in the vitreous, as> 90% of ICG remained intact in all for-
mulations for 15 days. All formulations behaved in a similar manner in
terms of ICG stability.
Calcein release from the liposomes was studied in serum and vitr-
eous. The formulations were relatively stable in serum for 5 h, but
thereafter significant release was observed already during the first day
(Fig. 3). Again, stability of the liposomes was better in the vitreous:
formulations A and C did not show any calcein leakage up to 3 days
whereas formulation B leaked 20% of the calcein dose in three days. At
6 days, all calcein had released from formulations B and C, while only
25% leaked from formulation A. At day 9, all calcein had leaked out
also from formulation A.
3.3. Molecular dynamics (MD) simulations
Results of the computational MD modelling are shown in Fig. 4. The
results for the calculation of the mass density profiles (Fig. 4A and C)
show peaks within the membrane in addition to outside the membrane
for the PEG distribution. This indicates that some of the PEG polymers
have entered into the lipid core of the membrane. This phenomenon has
been observed in PEGylated membrane systems that we have studied in
our previous computational work [43, 51, 52]. Visualizations of the
lipid membrane (Fig. 4B and D) show this phenomenon as well. Ad-
ditionally, the visualization shows that the membrane does not remain
in the fluid phase but has the structure of a gel or ripple phase. In our
prior studies of bilayers in the gel phase we did not observe the PEG
polymer penetration into the bilayer on the timescale over which the
simulations were performed [51, 53], however, the initial setup of these
studies was different: these systems were initiated in the gel phase with
the PEG lipids oriented outwards, into the water. In the current study,
the model was initialized at an elevated temperature and gradually
cooled down; in this respect, a better model of the relevant experi-
mental method of thin film hydration and extrusion. PEG penetration
into the highly ordered, but not gel phase, bilayer with cholesterol
present, however, has been observed in our prior studies [52].
Results for the molecular order parameter (Fig. 4E), indicate that
PEGylation affects this parameter for all non-PEG lipid constituents in
the membrane (lyso PC, DSPC, DPPC). The molecular order parameters
are noticeably increased for lyso PC and decreased for DSPC when PEG
is included in the formulation.
Table 1
Inclusion of PEG, the loading method of the ICG, size and the zeta potential of the prepared formulations.
Formulation PEG included ICG in aq. solution ICG mixed with the lipids Diameter (nm), PdI Zeta potential (mV)
A X X 96 ± 26, 0.047 ± 0.006 −4.44 ± 2.23
B X 123 ± 32, 0.083 ± 0.029 −4.68 ± 0.34
C X X 103 ± 26, 0.101 ± 0.044 −3.28 ± 0.54
31P NMR spectra of the phosphate group motion in the bilayers of all formulations was measured (Supplementary material, Fig. S1). Formulations A and C showed a
sharp peak at about −1 ppm at all measured temperatures. Formulations B and C showed a broad signal at −10 ppm at temperatures +27, +37 and+39 °C, while
formulation A only at +27 °C. All formulations had a tall peak at −1 ppm without broad signal at temperature of +50 °C.
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3.4. Effect of degraded ICG on contents leakage
Our experiments showed that ICG degradation and the fastest con-
tents leakage took place in formulation C (Fig. 2). Therefore, the effect
of ICG degradation products on the release of calcein was determined.
Liposomes with the same phospholipid compositions with and without
PEG were incubated with degraded ICG at different concentrations.
PEGylated liposomes released calcein at the levels of about 10–13%
during 24 h (Fig. 5). Degraded ICG did not increase calcein release. In
the case of the liposomes without PEG, presence of ICG degradation
products caused increasing trend in calcein leakage during 24 h in
concentration dependent manner (Fig. 5). The difference was sig-
nificant at 300 μM of ICG degradation products. Thus, only high con-
centrations of degraded ICG increase calcein leakage in the liposomes
without PEG.
3.5. Freeze-drying of ICG liposomes
Freeze-drying is considered to be an effective method to improve
the shelf-life stability of liposomes [54]. The most promising formula-
tion A was selected for freeze drying experiments. Freeze-drying was
performed using trehalose and sucrose as lyoprotectants, but without
encapsulated calcein. The average onset temperatures for phase tran-
sitions (+42.9–43.9 °C) did not show differences between the groups
(control, sucrose, trehalose).
The mean particle diameter and PdI were determined for each
lyoprotectant formulation at two freezing rates (Fig. 6). Freeze-drying
without any lyoprotectants increased the mean particle size 10-fold and
the PdI was 1.0. At a freezing rate of 10 °C/min, the particle size of
sucrose samples ranged between a 1.8-fold increase (4.5 mM) to no
change compared to the control (10.5 mM and 30mM) (Fig. 6, top). The
general trend shows that the low sucrose concentrations leads to larger
particles after freeze-drying. Increasing the lyoprotectant concentration
above 10.5mM does not yield much added benefit. The trehalose
samples showed a similar trend at all concentrations, with the exception
of 4.5 mM, where they show only a 1.2-fold increased size in compar-
ison to the control sample. The PdI of all freeze-dried samples was
higher than the control samples, ranging an 8-fold increase (4.5 mM) to
a 2-fold increase (15mM and 30mM). The zeta potential of the lipo-
somes remained unchanged after the freeze-drying (data not shown).
Similar trends can be seen for the samples with the slower freezing
rates of 2 °C/min (Fig. 6, bottom). The size of liposomes in the presence
Fig. 1. Top: Calcein release in various temperatures of formulation A (circle, solid line), formulation B (square, dashed line) and formulation C (triangle, dotted line).
The error bars represent the standard deviations (n=3, *p < .05). Bottom left: Differential scanning calorimetry measurements of the liposome formulations. Heat
flow graphs of formulation A (solid line), B (dashed line), and C (dotted line) (n=3). Bottom right: Light-triggered calcein release from the formulations. The
control samples were shielded from the light and kept at the same temperature (+37 °C) during the light exposure. The error bars represent the standard deviations
(n=3, *p < .05 and **p < .005).
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of 15mM of sucrose or trehalose was slightly increased (1.1-fold)
compared to the control, while significant increase was seen with the
lyoprotectant concentration of 4.5mM. The PdI showed the same trend
as the other freezing rate. Retention of hydrophilic calcein was shown
to be poor during the freeze-drying process (Supplementary material)
with most the cargo escaping upon reconstitution of the dry powder.
4. Discussion
Drug delivery to the posterior segment of the eye is challenging, but
on the other hand the transparent eye is very well suited for the use of
light triggered DDS [55]. Likewise, cancer is a unique target for drug
delivery, which often requires very potent drug substances with pos-
sible severe adverse effects. Site-specific drug release could help in re-
ducing drug doses and adverse drug effects. Treatment of various skin
conditions is applicable for external light induced drug release. Fur-
thermore, light triggered liposomes can be applied during surgery with
fiber optics and the drug could be released at the desired place and
time. If suitable stability properties of the DDS can be achieved while
retaining the necessary sensitivity for the light activation, ICG lipo-
somes may offer an attractive solution to several drug delivery pro-
blems. It has been known for a long time that inclusion of PEG coating
or cholesterol in the bilayer improve the liposomal stability in biolo-
gical environments [56–59]. Unfortunately, cholesterol hinders the
heat based release method during light activation. An optimal balance
must be found with the stability and light triggering sensitivity. In this
study, the localization of the ICG molecules has shown to have an im-
pact on the stability of the liposomes, even though the formulations
retain their light activated release functions regardless of the localiza-
tion of the ICG.
In this paper, three different formulations of ICG encapsulation
method were studied. Previous results have shown that the ICG in the
aqueous solution is wrapped by the PEG chains (Formulation A)
showing only limited interaction with the lipid bilayers [22]. If a PEG
corona is not present, the ICG will be embedded within the bilayer
(Formulation B). If ICG is mixed with the phospholipids in the presence
of PEGylated lipids (Formulation C), the localization ICG is difficult to
determine. The molecular dynamics simulations suggest that the ICG
remains in the bilayer, at least for short time periods. Significant ICG
migration may occur between the lipid bilayer and the PEG corona over
long time periods. The differences in the results between formulations A
and C indicate that not all ICG molecules escape from the lipid layers to
the PEG corona in formulation C. The zeta potentials of the liposomes
were in the same range. The slightly higher mean diameter of the for-
mulation B could be attributed to the lack of steric stabilization and
some liposome aggregation, but the size differences were not sig-
nificant. ICG or ICG derivatives can be covalently conjugated with
phospholipids [60–63]. In theory, these formulations would have si-
milar effects on the phospholipid bilayer as formulation A, but they are
outside the scope of this article. The ICG – lipid conjugates are planned
to be characterized in the follow up studies.
Phospholipids in liposomal bilayers show 31P chemical shift aniso-
tropy patterns due to their orientation in the magnetic field of NMR
[49, 50, 64]. In liposomal phospholipids the spectra usually exhibit
sharp peaks and broad signals depending on the phospholipid molecule
types and the interactions with the surroundings and size of the lipo-
some. All of the formulations had a phosphate peak at 0 ppm due to the
rapid tumbling of liposomes with about 100 nm diameter [65] (Fig. S1).
The tall peaks at lower ppm found in spectra of formulation A and C are
due to the DSPE-PEG structure [64, 66, 67]. The broad signal at about
Fig. 2. Stability of formulations A (circle, solid line), B (square, dashed line), and C (triangle, dotted line) during 12 days in HEPES buffer (20mM HEPES, 140mM
NaCl, pH 7.4) at +4 °C (top row), +22 °C (middle row), and+37 °C (bottom row). Mean size of the liposomes (left), the stability of ICG (center), and the contents
release (right) were measured. The error bars represent the standard deviations (n=3, *p < .05 and **p < .01).
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−10 ppm indicates restricted movement of the phospholipids and
amine phosphate interactions between phospholipids or with other
molecules [47, 64, 68, 69]. At increased temperatures the phospholi-
pids move more freely in the bilayer resulting in a reduction of the
broad signal with formulation A. In case of formulations B and C, the
broad signal at elevated temperatures (+37 and+39 °C) may be due to
interaction between the phosphate of the lipids and the amine of ICG
[68, 69]. Thus, it is uncertain if phospholipid movement is increased or
not in those cases. In case of formulation C, the broad signal in the 31P
NMR spectra shows that ICG is located at the lipid bilayer instead of the
PEG corona (Fig. S1eC).
The localization of ICG had an effect on the leakage of calcein from
the liposomes during a heat gradient experiment (Fig. 1). Formulation
A and formulation C were the most and the least stable, respectively.
Notably, formulation C released some calcein already at +37 °C sug-
gesting that premature contents release could take place in vivo. The
DSC results showed Tm lowering of only a 1 °C for formulation C as
compared to formulations A and B. The actual difference in the lipid
bilayer fluidity may be more significant, since DSC is not sensitive en-
ough to detect the ripple phase that is normally present below Tm [15].
Even though differences were seen in the light activation experiments
(Fig. 1), all formulations had acceptable light triggering properties.
Formulation C was the most sensitive formulation in terms of light
triggered release, but it also had the most prominent passive leakage at
+37 °C. This result is in accordance with the heat release and calori-
metric experiments.
Similarly, the storage in aqueous buffer at temperatures +4, +22
and+37 °C showed inferior stability of formulation C (Fig. 2). De-
gradation of ICG and the leakage of calcein were most pronounced with
formulation C at +22 and+37 °C. The size of the formulations
remained unchanged, which indicates that the leakage from formula-
tion C is mediated by the bilayer changes and not due to the aggrega-
tion processes. Because the difference between formulations B and C is
the presence of the PEG, the increased ICG degradation in formulation
C is due to the effect of the PEG molecules. Furthermore, the difference
between formulations A and C is the location of the ICG molecules.
Thus, it can be speculated that some level of PEG interaction with the
bilayer is enabled by the lipid embedded ICG molecules. This interac-
tion may cause leakage of ICG molecules into the aqueous solution and
eventual degradation [36]. The slightly larger diameter of formulation
B may be due to the lack of steric stabilization by PEG coating, leading
to some aggregation of the liposomes.
In serum and vitreous, larger liposomal diameters of about
150–200 nm were observed. This may be due to adherence of biological
compounds [70, 71]. In the vitreous, the ICG remained stable, while all
of the formulations showed decrease in ICG absorbance in the serum.
About half of the ICG was degraded at 15 days in the vitreous. Fur-
thermore, calcein retention was poor in the serum and much better in
the vitreous: most calcein leaked out in one day in the serum, whereas
complete release took 6–9 days in the vitreous. The serum has higher
protein concentration (60–80 g/L) than the vitreous (0.28–1.36 g/L)
[55, 72–76]. The proteins may adhere to the liposomes [71], interact
with the bilayers and induce leakage [77, 78]. Formulation B showed
higher initial contents leakage, in both serum and vitreous, compared to
formulations A and C. Formulation B lacks the PEG coating making it
more sensitive to attachment of serum and vitreous components. In
vitreous, the PEG formulations were very stable for 3 days, which
would be a reasonable time frame for liposomes to reach the retinal
targets after intravitreal injections [55]. The formulations were rela-
tively stable up to 5 h in serum, which may be enough for the liposomes
Fig. 3. Stability of formulations A (circle, solid line), B (square, dashed line), and C (triangle, dotted line) at +37 °C in serum (top row) and vitreous (bottom row).
Mean size of the liposomes (left), the stability of ICG (center), and the contents release (right) were measured. The error bars represent the standard deviations
(n=3, *p < .05 and **p < .01). The insert in the top rightmost graph shows the calcein release during the first 5 h.
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to reach the common target sites [8, 79]; the temporal margin for the
light activation is clearly shorter in the blood circulation than in the
vitreous.
Overall, the passive calcein leakage was the most prominent from
formulation C with PEG corona and ICG in the bilayer (Table 1). The
passive leakage would be undesirable in therapy, as it would lead to
uncontrolled drug release off-target. Molecular dynamics simulations
were used to elucidate the possible reasons for these phenomena
(Fig. 4). PEG remains, for the most part, outside the phospholipid bi-
layer in case of formulation A and do not disrupt the ordered lipid layer
and cause passive leakage (Fig. 4A and B). In the case of formulation C,
when ICG is within the PEGylated lipid bilayer (Fig. 4C and D), sig-
nificant PEG penetration into the bilayer was also seen. The ICG is lo-
calized near to the liposomal surface, theory of which is supported by
31P NMR data indicating ICG interaction with the phospholipid head
groups. Because all the components of the bilayer affect the stability of
the liposome [12, 80], ICG may cause a slight disruption in the ordered
phospholipid phase, thereby enabling insertion of PEG into the lipid
layer and its further disruption. In the visualization image from mole-
cular dynamics simulations, large areas of the bilayer have the PEG
molecules displacing the phospholipids (Fig. 4D). As PEG is sig-
nificantly more hydrophilic than the phospholipids, these PEG domains
may allow the leakage of hydrophilic calcein from the liposomes.
Likewise, the PEG insertion into the bilayer may pull out some ICG and
increase the degradation rate of the ICG (Fig. 2). However, it seems that
the degraded ICG did not induce the leakage of calcein (Fig. 5) and it is
unlikely that the degraded ICG has any major consequences on lipo-
some stability.
Altogether we see, from the computational modelling results, evi-
dence that PEG disrupts the membrane structure, possibly affecting the
phase behavior of the bilayer. This could manifest itself as a decrease of
the temperature of the main phase transition (Fig. 1), a broadening of
the temperature range of the transition or a decrease in the latent heat
associated with the transition. This provides evidence that PEGylation
of the membrane will, in fact, increase the extent to which the mem-
brane structure would potentially be disrupted by presence of the ICG
Fig. 4. Mass density profile for the PEGylated membrane with ICG in the water phase (A), and visualization of the PEGylated membrane (B). PEG polymers are shown
in green, ICG shown in purple and phosphate head groups in red. Mass density profile and membrane visualization for PEGylated membrane with ICG inside the lipid
bilayer (C and D). Molecular order parameter for the three systems constituent lipids of the membrane with ICG inside the lipid bilayer (E). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 5. The effect of degraded ICG on the contents leakage from the formulations with PEG (left) and without PEG (right) during 1 h and 24 h in +37 °C. The amount
of initial ICG is shown under the horizontal axis. Control samples were without any degraded ICG. The error bars represent the standard deviations (n=3,
*p < .01).
Fig. 6. The particle diameter and PdI of liposomes freeze-dried at the rate of 10 °C/min (top) and 2 °C/min (bottom). The control samples were not freeze-dried. The
error bars represent the standard deviations (n=2, *p < .05).
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in the membrane. This in turn leads to less stability during the storage
at elevated temperatures (Figs. 2 and 3). The phenomena was also
shown in our previous studies [22], where although the ICG was placed
in the water phase, passive contents leakage was seen with very high
ICG concentrations. Obviously, there is a limit on the binding capacity
of the PEG and any unbound ICG localizes to the lipid bilayer causing
instability.
The molecular order parameter was changed due to the inclusion of
PEG into the bilayer (Fig. 4E). For the case of a lipid bilayer in the gel
phase, a change characterized by a collective tilt of the acyl tails that
adopt an all-trans conformation was seen. This indicates a disruption of
the gel structure, but detailed interpretation of the observed collective
tilt and evaluation of its significance in relation to the liposomal sta-
bility is difficult. The hydrophilic PEG domains within the bilayer are
the more likely route of calcein leakage than the altered conformation
of the acyl tails. Nevertheless, the results show that the PEG insertion
affects the phospholipid ordering and this change may be significant for
other bilayer properties [81].
We also assessed freeze-drying of formulation (A) as means of sta-
bilization. Sucrose and trehalose were selected as lyoprotectants, since
these have been used in intravitreal anti-VEGF injections (Eylea,
Lucentis and Avastin). The impact of the freezing rate was studied,
because it may affect the conservation of lipid bilayers [54, 82]. In our
study, no difference between the freezing rates was seen in terms of
liposomal size, polydispersity and Tm (Fig. 6). Overall, the freeze-drying
did not affect the Tm of the liposomes, which is in accordance with
previous results [54, 83]. The particle size of the liposomes was pre-
served by adding at least 15mM of sucrose or trehalose, although the
PdI was slightly increased (Fig. 7). 15mM was about the equivalent of a
2:9 lipid-lyoprotectant ratio (w/w), based on their molecular weights
and concentrations. The ratio is on the lower side of the findings in the
literature that have reported ratios ranging from 1:5 to 1:10 [83, 84].
Even though the size of the liposomes remained unchanged, significant
calcein leakage was noted during the freeze-drying process (Supple-
mentary material). Calcein crystallizes as water is removed and is
poorly reconstituted leading to low retention. Although, the calcein
retention during the freeze-drying was poor, the process is probably
suitable for ICG liposomes encapsulating lipophilic drugs. Those pre-
ferably remain in the lipid bilayer and the temporary disruption of the
ordered state does not cause content leakage.
5. Conclusions
The stability of ICG liposomes with different ICG molecule loading
protocols was studied. The most stable formulation included PEG
coating and ICG inclusion in the hydration solution. The stability in
common storage conditions (+4 °C and+22 °C) was acceptable. In
biological environments, vitreous and serum at +37 °C, the liposomes
remained sufficiently stable for 3 days and 5 h, respectively. This should
be adequate for the most common clinical treatment protocols. The
content leakage mechanisms were elucidated with in vitro and in silico
experiments, and PEG penetration into the lipid bilayer was found to be
possible major cause for the instability. The interaction of PEG and lipid
membrane localized molecules should be taken in to account during
formulation design. Finally, freeze-drying was determined to be ap-
plicable for long term storage of ICG liposomes, although further re-
search is needed to determine viable cargoes.
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